What is melanotan II? Structure, research and status

Melanotan II is a synthetic cyclic peptide modeled on alpha-MSH. It was tested in a few small human studies in the 1990s and has never been approved.

Complete guide10 min read

Key takeaway

Melanotan II (MT-II) is a cyclic analog of a short fragment of alpha-MSH, the hormone that signals skin cells to make pigment. Three small published trials in 23 men reported skin darkening, erections, nausea and yawning. Case reports describe melanoma, changing moles, priapism and systemic toxicity after use of unlicensed products, without proving cause. FDA lists safety concerns, and UK and Australian regulators warn against tanning products that contain it.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Melanotan II is not approved by the FDA for any use.” (this article)
ClassSkin & cosmetic
Body systemsSkin & connective tissue
Studies cited8 in this article · 8 across 1 article on Melanotan II
Related productsCopper peptides and melanocortin fragments

Melanotan II is a ring-shaped peptide of seven amino acids, designed at the University of Arizona in the late 1980s. It darkens skin and acts on brain receptors tied to appetite and sexual function. A close relative, bremelanotide, became the FDA-approved drug Vyleesi in 2019. Melanotan II remains unapproved, and US, UK and Australian regulators have warned about products sold under its name.

Quick answer: Melanotan II is an experimental melanocortin receptor agonist. Melanotan II is not approved by the FDA for any use. FDA plans to discuss it at a compounding advisory committee meeting before the end of February 2027. It is a different molecule from afamelanotide (melanotan I) and from bremelanotide.

Vitrapep does not sell melanotan II; this page is a reference summary of published research and regulatory information.

What is melanotan II?

PubChem describes melanotan II as a synthetic cyclic heptapeptide, a peptide of seven amino acids, and an analog of alpha-melanotropin (alpha-MSH) [1]. A lactam bond between the side chains of aspartic acid and lysine closes the ring.

In 1989, Al-Obeidi, Hadley, Hruby and colleagues at the University of Arizona described cyclic lactam analogs of alpha-MSH designed with molecular dynamics simulations [2]. The analog with the melanotan II structure was 90 times more potent than alpha-MSH in a lizard skin assay [2]. The same group later tested melanotan I for tanning and melanotan II for male erectile dysfunction (Hadley and Dorr, 2006).

PubChem lists "melanotan I" as a synonym for afamelanotide, a linear peptide of 13 amino acids approved as Scenesse (PubChem CID 16197727). Vitrapep's afamelanotide guide covers that drug.

Table 1

What is melanotan II

FactDetail
Other namesMT-II, MTII, melanotan-II [1]
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 [1]
Parent hormoneAnalog of the 4-10 fragment of alpha-MSH [3]
Molecular formulaC50H69N15O9 [1]
Molecular weight1024.2 g/mol [1]
CAS number121062-08-6 [1]
ClassMelanocortin receptor agonist; binds MC1, MC3, MC4 and MC5 receptors [6]
FDA approvalNone
Closest approved relativeBremelanotide (Vyleesi), approved June 21, 2019

How does melanotan II work?

Melanotan II activates melanocortin receptors, the receptors that respond to alpha-MSH. In a 1997 cell study, Schiöth and colleagues measured its binding to human MC1, MC3, MC4 and MC5 receptors [6]. Its developers later called it "a non-selective melanocortin receptor agonist" (Wessells et al., 2000).

The MC1 receptor on skin controls dark eumelanin pigment, while MC3 and MC4 receptors act in the brain [7]. In a 1997 mouse study, melanotan II acting on brain receptors reduced feeding in four models of overeating [7]. A blocker of MC3 and MC4 receptors, SHU9119, completely prevented the effect. These are animal findings, not human data.

A 2007 review by the group said MC4 is emerging as the main receptor for melanocortin-induced erections (King et al., 2007).

Is melanotan II approved or being studied for any use?

Drugs@FDA lists no approved product containing melanotan II. In Australia, the TGA says it is a prescription-only medicine, but no product containing it is on the Australian Register of Therapeutic Goods [14].

One study is registered. NCT07437560 is a Phase 2, randomized, placebo-controlled trial in adults with stable nonsegmental vitiligo, a condition in which skin loses pigment. All participants receive narrowband UV-B light therapy for 24 weeks, plus melanotan II or placebo. It plans to enroll about 60 adults at one site in Shenzhen, China. The record lists it as recruiting, with no posted results.

What did the key melanotan II trials show?

Three small Arizona trials are the published controlled human evidence we found. All enrolled only men, and none measured long-term safety.

Dorr and colleagues, 1996. This pilot Phase 1 study enrolled three healthy men in a single-blind, placebo-controlled design over two weeks [3]. Two had darker skin on the face, upper body and buttocks a week after treatment ended. Spontaneous erections occurred, often after a stretching and yawning complex.

Wessells and colleagues, 1998. Ten men with erectile dysfunction of no known physical cause entered a double-blind, placebo-controlled crossover study [4]. Eight developed clinically apparent erections with melanotan II. Mean time with tip rigidity above 80% was 38.0 minutes, versus 3.0 with placebo (p=0.0045).

Wessells and colleagues, 2000. Ten men with erectile dysfunction and physical risk factors entered a similar crossover study [5]. Erections occurred in 12 of 19 melanotan II sessions and 1 of 21 placebo sessions. Reported sexual desire was significantly higher after melanotan II.

Table 2

What did the key melanotan II trials show

StudyPopulation and sizeDesignMain reported findings
Dorr et al., 1996 [3]3 healthy menPilot Phase 1; single-blind, placebo-controlled; two weeksDarker skin in 2 of 3; spontaneous erections; mild nausea; somnolence and fatigue in 1
Wessells et al., 1998 [4]10 men with psychogenic erectile dysfunctionDouble-blind, placebo-controlled crossover; six-hour monitoringErections in 8 of 10; rigidity time 38.0 vs 3.0 minutes
Wessells et al., 2000 [5]10 men with erectile dysfunction and organic risk factorsDouble-blind, placebo-controlled crossoverErections in 12 of 19 sessions vs 1 of 21 on placebo; rigidity time 45.3 vs 1.9 minutes
NCT07437560About 60 adults with stable nonsegmental vitiligoPhase 2; randomized, placebo-controlled, added to UV-B therapy; 24 weeksRecruiting; no results posted

These are human data from tiny, short studies. Palatin Technologies later developed an analog, PT-141, now called bremelanotide (Hadley and Dorr, 2006).

What side effects have been reported with melanotan II?

In trials. Mild nausea was reported in the 1996 pilot study, and one man had grade II somnolence and fatigue [3]. In 1998, nausea, stretching and yawning, and decreased appetite were more frequent than with placebo, but none needed treatment [4]. In 2000, 4 of 19 melanotan II sessions involved severe nausea [5].

In case reports. Most later safety data come from users of unlicensed products. FDA says published case reports "discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism" [11].

  • Moles and melanoma. A 2017 review noted rising reports of changing moles and new, sometimes dysplastic, moles after melanotan I or II use [9]. It counted four case reports of melanoma arising from existing moles, but said conclusive evidence of a link was lacking. A German report described new and darkening moles 24 hours after a single use (Schulze et al., 2014).
  • Systemic toxicity. A 39-year-old man developed a fast heart rate, sweating, tremor, rhabdomyolysis (muscle breakdown) and kidney dysfunction after using a product bought online [10]. Testing confirmed melanotan II. He spent three days in intensive care and improved.
  • Priapism. A 2021 report described a prolonged erection that needed surgical decompression (Mallory et al., 2021). The authors said only two earlier cases had been published.
  • Brain and kidney. One report linked melanotan use to posterior reversible encephalopathy syndrome, a form of brain swelling (Kaski et al., 2013). Another described a renal infarction (Peters et al., 2020).

Case reports cannot show how often an event happens or prove that the peptide caused it. Several involved products of unknown content or other exposures, such as sunbed tanning (Hjuler and Lorentzen, 2014).

Regulator reports. The UK MHRA received 16 suspected adverse reaction reports for melanotan II from 2012 through 2022 [13]. MHRA notes that a report does not prove cause.

The Vyleesi label describes bremelanotide as a cyclic heptapeptide "with a free acid at the carboxyl terminus" [8]. Melanotan II ends in an amide instead [1]. The 2007 review called PT-141 "the carboxylate derivative of MT-II" (King et al., 2007).

FDA approved Vyleesi on June 21, 2019, as a new molecular entity (Drugs@FDA, NDA 210557). Its label covers premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [8]. Label warnings include transient rises in blood pressure and focal hyperpigmentation, reported in 1% of trial patients. Nausea occurred in 40% of patients in the Phase 3 trials [8]. See Vitrapep's PT-141 guide.

These findings describe bremelanotide and do not establish the safety of melanotan II.

Table 3

How is melanotan II related to bremelanotide and afamelanotide

FeatureMelanotan IIBremelanotideAfamelanotide
StructureCyclic; 7 amino acids; amide endCyclic; 7 amino acids; free acid endLinear; 13 amino acids
Molecular formulaC50H69N15O9C50H68N14O10C78H111N21O19
First FDA approvalNoneJune 21, 2019October 8, 2019 (NDA 210797)
Approved useNoneAcquired, generalized HSDD in premenopausal womenPain-free light exposure in adults with erythropoietic protoporphyria

What is the regulatory status of melanotan II?

United States. In 2007, FDA sent a warning letter to an online seller marketing melanotan II as a tanning product. A later FDA notice says the letter called it a new drug that needed an approved application before sale (FDA, 2016).

Compounding. FDA's safety-risks page showed melanotan II in 503A category 2, for substances that may present significant safety risks, from September 29, 2023 [11]. The current version, dated April 22, 2026, lists it among nominations later withdrawn. The entry warns of possible immunogenicity, an unwanted immune response, linked to aggregation or peptide-related impurities. FDA plans an advisory committee meeting before the end of February 2027 to discuss melanotan II for the 503A bulks list [12]. The October 2026 HHS draft enforcement policy lists six peptides in Appendix A; melanotan II is not one (HHS, 2026). See Vitrapep's summary of the HHS policy.

Product quality. A 2015 study of melanotan II vials from three online shops found 43% to 88% of the labeled content (Breindahl et al., 2015). Vials from two shops held 4.1% to 5.9% unknown impurities. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

United Kingdom. MHRA classifies injectable melanotan II products and pens as medicines. Nasal sprays count as medicines only when sold with claims to treat or prevent disease [13]. Selling, supplying or advertising unauthorized medicines is not permitted, and MHRA says it has removed melanotan products from the market for over 10 years.

Australia. TGA says melanotan II is not approved as a tanning agent [14]. In August 2026, it reported that five seized spray bottles with identical labels varied more than twofold in estimated melanotan II content. It issued 27 infringement notices to the alleged supplier [14].

Sport. The WADA 2026 Prohibited List does not name melanotan II. Its S0 class covers unlisted substances with no current government approval for human therapeutic use (peptides on the 2026 WADA list).

What is still unknown about melanotan II?

The controlled human evidence is three trials in 23 men, with follow-up of hours to weeks. None of these trials measured long-term safety or enrolled women. Whether melanotan II raises melanoma risk is unresolved [9]. Identity and purity vary outside regulated manufacturing.

Frequently asked questions

Is melanotan II FDA-approved?

No. Drugs@FDA lists no approved product containing it. FDA plans to discuss it at a compounding advisory committee meeting before the end of February 2027.

Is melanotan II the same as melanotan I?

No. PubChem lists melanotan I as a synonym for afamelanotide, a linear peptide approved as Scenesse. Melanotan II is shorter and cyclic.

Is melanotan II the same as PT-141?

No, but they are close relatives. PT-141, now bremelanotide, differs only at the carboxyl end and is approved as Vyleesi.

What side effects were reported in melanotan II trials?

Nausea, yawning, decreased appetite, somnolence, fatigue, skin darkening and spontaneous erections. The trials were too small to define a safety profile.

Does melanotan II cause melanoma?

That has not been established. Case reports describe melanoma during or after use, but a 2017 review said conclusive evidence of a link was lacking.

Is melanotan II legal in the UK or Australia?

MHRA treats injectable products as medicines that may not be sold without authorization. TGA says no melanotan II product is approved there.

Is melanotan II banned in sport?

The WADA 2026 list does not name it. Its S0 class covers substances not listed elsewhere that lack government approval for human therapeutic use.

What to know now

  • Melanotan II is a cyclic analog of alpha-MSH, described in 1989.
  • Three small trials in 23 men reported skin darkening, erections, nausea and yawning.
  • Case reports describe melanoma, mole changes, priapism and toxicity, without proving cause.
  • It has no FDA approval; FDA cites immunogenicity and case reports.

What we’re watching

  • FDA's Pharmacy Compounding Advisory Committee meeting on melanotan II, planned before the end of February 2027.
  • Results from the Phase 2 vitiligo trial NCT07437560.
  • Further MHRA and TGA enforcement actions on melanotan tanning products.

More for skin & connective tissue

All 26 compounds for skin & connective tissue

Sources: National Center for Biotechnology Information 2026; Al-Obeidi 1989, Journal of Medicinal Chemistry, 32; Dorr 1996, Life Sciences, 58; Wessells 1998, Journal of Urology, 160; Wessells 2000, Urology, 56; Schiöth 1997, Peptides, 18; Fan 1997, Nature, 385; U.S. National Library of Medicine 2026; Habbema 2017, International Journal of Dermatology, 56; Nelson 2012, Clinical Toxicology, 50; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; Medicines and Healthcare products Regulatory Agency 2024; Therapeutic Goods Administration 2026. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 92432, melanotan II. https://pubchem.ncbi.nlm.nih.gov/compound/92432
  2. Al-Obeidi, F., Castrucci, A. M., Hadley, M. E., & Hruby, V. J. (1989). Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: Design based on molecular dynamics. Journal of Medicinal Chemistry, 32(12), 2555-2561. https://doi.org/10.1021/jm00132a010
  3. Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777-1784. https://doi.org/10.1016/0024-3205(96)00160-9
  4. Wessells, H., Fuciarelli, K., Hansen, J., Hadley, M. E., Hruby, V. J., Dorr, R., & Levine, N. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
  5. Wessells, H., Gralnek, D., Dorr, R., Hruby, V. J., Hadley, M. E., & Levine, N. (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology, 56(4), 641-646. https://doi.org/10.1016/s0090-4295(00)00680-4
  6. Schiöth, H. B., Müceniece, R., Mutulis, F., Prusis, P., Lindeberg, G., Sharma, S. D., Hruby, V. J., & Wikberg, J. E. (1997). Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides, 18(7), 1009-1013. https://doi.org/10.1016/s0196-9781(97)00079-x
  7. Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J., & Cone, R. D. (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 385(6612), 165-168. https://doi.org/10.1038/385165a0
  8. U.S. National Library of Medicine. (2026). Vyleesi (bremelanotide) injection: prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
  9. Habbema, L., Halk, A. B., Neumann, M., & Bergman, W. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: A review. International Journal of Dermatology, 56(10), 975-980. https://doi.org/10.1111/ijd.13585
  10. Nelson, M. E., Bryant, S. M., & Aks, S. E. (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology, 50(10), 1169-1173. https://doi.org/10.3109/15563650.2012.740637
  11. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  12. U.S. Food and Drug Administration. (2026). Meeting of the Pharmacy Compounding Advisory Committee (meeting to be held before the end of February 2027). https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
  13. Medicines and Healthcare products Regulatory Agency. (2024). FOI 24/274: Side effects reports of melanotan II products. https://assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d55a/Final_Redaction_FOI_24_274.pdf
  14. Therapeutic Goods Administration. (2026). Melanotan II tanning peptide products found to be inconsistently dosed (safety advisory, August 17, 2026). https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/melanotan-ii-tanning-peptide-products-found-be-inconsistently-dosed